New hope for tough cancers: revumenib trial shows promise

NCT ID NCT05731947

Terminated Disease control Sponsor: Syndax Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how the drug moves through the body, and how well it controlled the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER SOLID TUMORS

Contacts and locations

Locations

Gabrail Cancer Center

Canton, Ohio, 44718, United States
Honor Health Research Institute

Scottsdale, Arizona, 85258, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

Manhattan, New York, 10065, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.